BioNano Genomics Inc vs Solaredge Technologies Inc — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while Solaredge Technologies Inc trades at $56.35 (market cap $3.38B). The key difference: Solaredge Technologies Inc is far larger — about 256.1× BioNano Genomics Inc's market cap, and Solaredge Technologies Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | SEDG | |
|---|---|---|
Market Cap | $13.20M | $3.38B |
Sector | Health | Technology |
52-Week High | $4.92 | $78.51 |
52-Week Low | $1.09 | $24.42 |
Enterprise Value | $15.81M | $3.31B |
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
SolarEdge Technologies (SEDG) trades at $52.13, down 5.53% amid bearish technical signals and mixed fundamentals. The stock shows negative profitability with a -28.56% net margin and -72.5% ROE, though recent quarters saw earnings beats. Revenue declined from $3.1B in 2022 to $1.18B in 2025, reflecting solar market challenges. Analyst sentiment is cautious with a $35.56 consensus target below current price, while technical indicators show bearish momentum with key support at $49.
SEDG faces significant headwinds with persistent losses and declining revenue, though operational cash flow turned positive in 2025. Investment opportunity exists if solar demand recovers, but risks include intense competition, policy uncertainty, and high debt levels. The stock remains speculative with substantial downside risk to analyst targets.
Trailing returns across standard periods
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →